Gregory Renza
Stock Analyst at Truist Securities
(4.18)
# 467
Out of 5,139 analysts
244
Total ratings
43.69%
Success rate
18.15%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Buy | $62 → $66 | $54.73 | +20.59% | 5 | Jan 12, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $41 → $40 | $33.26 | +20.26% | 13 | Jan 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $798 → $820 | $733.04 | +11.86% | 2 | Jan 8, 2026 | |
| AMGN Amgen | Maintains: Hold | $318 → $319 | $330.41 | -3.45% | 19 | Jan 8, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $59 → $60 | $35.84 | +67.41% | 14 | Jan 6, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $38 | $27.19 | +39.76% | 8 | Dec 24, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Buy | $14 → $18 | $10.14 | +77.51% | 5 | Dec 11, 2025 | |
| CATX Perspective Therapeutics | Assumes: Buy | $8 → $12 | $2.33 | +415.02% | 7 | Nov 24, 2025 | |
| NRIX Nurix Therapeutics | Assumes: Buy | $23 → $30 | $19.21 | +56.17% | 12 | Nov 24, 2025 | |
| GILD Gilead Sciences | Assumes: Buy | $145 → $140 | $124.91 | +12.08% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $12.79 | +126.74% | 10 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.85 | +88.03% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $104.26 | +34.28% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.21 | +72.74% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $10 | $6.51 | +53.61% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $338.19 | +18.28% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $27.05 | +88.54% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $117.10 | +19.56% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $45 → $50 | $43.96 | +13.74% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $25.99 | +0.04% | 16 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.62 | +120.99% | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $5 | $1.52 | +228.95% | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $182 → $172 | $169.41 | +1.53% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $113 → $38 | $73.53 | -49.00% | 14 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $6.78 | +76.99% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $6.68 | +109.58% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $19.16 | -6.05% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $1.53 | +3,037.25% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $7.26 | +175.48% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $0.71 | +2,157.97% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $15.06 | +1,095.22% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $0.90 | +8,813.65% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.34 | +8,715.75% | 3 | Jun 2, 2020 |
CG Oncology
Jan 12, 2026
Maintains: Buy
Price Target: $62 → $66
Current: $54.73
Upside: +20.59%
Viridian Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $41 → $40
Current: $33.26
Upside: +20.26%
Regeneron Pharmaceuticals
Jan 8, 2026
Maintains: Buy
Price Target: $798 → $820
Current: $733.04
Upside: +11.86%
Amgen
Jan 8, 2026
Maintains: Hold
Price Target: $318 → $319
Current: $330.41
Upside: -3.45%
IDEAYA Biosciences
Jan 6, 2026
Maintains: Buy
Price Target: $59 → $60
Current: $35.84
Upside: +67.41%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $27.19
Upside: +39.76%
Fulcrum Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $14 → $18
Current: $10.14
Upside: +77.51%
Perspective Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $8 → $12
Current: $2.33
Upside: +415.02%
Nurix Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $23 → $30
Current: $19.21
Upside: +56.17%
Gilead Sciences
Nov 24, 2025
Assumes: Buy
Price Target: $145 → $140
Current: $124.91
Upside: +12.08%
Nov 24, 2025
Initiates: Buy
Price Target: $29
Current: $12.79
Upside: +126.74%
Nov 24, 2025
Initiates: Buy
Price Target: $11
Current: $5.85
Upside: +88.03%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $104.26
Upside: +34.28%
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $5.21
Upside: +72.74%
Nov 24, 2025
Initiates: Hold
Price Target: $10
Current: $6.51
Upside: +53.61%
Nov 24, 2025
Initiates: Buy
Price Target: $400
Current: $338.19
Upside: +18.28%
Nov 24, 2025
Initiates: Buy
Price Target: $51
Current: $27.05
Upside: +88.54%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $117.10
Upside: +19.56%
Jul 8, 2025
Downgrades: Sector Perform
Price Target: $45 → $50
Current: $43.96
Upside: +13.74%
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $25.99
Upside: +0.04%
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.62
Upside: +120.99%
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.52
Upside: +228.95%
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $169.41
Upside: +1.53%
Apr 16, 2025
Maintains: Sector Perform
Price Target: $113 → $38
Current: $73.53
Upside: -49.00%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $6.78
Upside: +76.99%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $6.68
Upside: +109.58%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $19.16
Upside: -6.05%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $1.53
Upside: +3,037.25%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $7.26
Upside: +175.48%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $0.71
Upside: +2,157.97%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $15.06
Upside: +1,095.22%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $0.90
Upside: +8,813.65%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.34
Upside: +8,715.75%